News for hackers. Stuff that matters.
Re:Unconventional Case Study of Neoadjuvant Oncolytic Viroth... by XorNot on Monday September 09, 2024 @03:42AM (#41486294)
You're not adding money to the mix.

If a company or research group wants to sponsor an experimental treatment with patient approval and waiver free of charge, that's one thing.

But they almost immediately turn around and say " oh we'll need to cover costs..." and suddenly the incentive is very different.

There are no comments on this comment yet.